Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended 30 September 2026 and Half Year ended 30 September 2026
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Date of Board Meeting / Approval: 04 November 2026
Audit Opinion: Unmodified opinion (clean)
Auditor's Comment: Nothing has come to our attention that causes us to believe that the Statement contains any material misstatement
Key Financial Highlights [₹ in Lakhs]
Standalone Results:
Revenue from Operations:
- Q2 FY27: ₹18,290.97 (vs Q1 FY27: ₹16,558.35; Q2 FY26: ₹16,005.82)
- H1 FY27: ₹34,849.32 (vs H1 FY26: ₹32,324.22)
Total Income:
- Q2 FY27: ₹18,303.10
- H1 FY27: ₹34,897.49
Net Profit:
- Q2 FY27: ₹1,188.23 (vs Q1 FY27: ₹324.29; Q2 FY26: ₹1,518.03)
- H1 FY27: ₹1,512.52 (vs H1 FY26: ₹2,867.08)
EPS (Basic):
- Q2 FY27: ₹3.40
- H1 FY27: ₹4.33
Other Equity:
- As at 30/09/2026: ₹12,474.85
- As at 31/03/2026: ₹10,951.14
Cash and Cash Equivalents:
- As at 30/09/2026: ₹793.62
- As at 31/03/2026: ₹161.16
Debt:
Total Borrowings (Non-current + Current):
- As at 30/09/2026: ₹22,361.45
- As at 31/03/2026: ₹21,545.03
Consolidated Results:
Revenue from Operations:
- Q2 FY27: ₹18,290.97
- H1 FY27: ₹34,849.32
Net Profit:
- Q2 FY27: ₹852.62
- H1 FY27: ₹1,176.87
Profit attributable to:
- Owners of the company: ₹913.03 (Q2), ₹1,237.28 (H1)
- Non-controlling interest: (₹60.41) (Q2), (₹60.41) (H1)
EPS (Basic):
- Q2 FY27: ₹2.44
- H1 FY27: ₹3.37
Segment-wise Performance:
The Company has only one segment of activity namely "Pharmaceuticals"
Corporate Actions:
- During the quarter, 27,530 equity shares of ₹10 each fully paid up were allotted upon exercise of vested options pursuant to the "Wanbury ESOP-2016"
- Increase in paid-up share capital by ₹2.75 Lakhs and Securities Premium account by ₹55.56 Lakhs
Other Significant Information:
- During the quarter ended 30 September 2026, the Company incorporated a subsidiary, Wanbury Skin Health Limited
- Investment of ₹4.10 lakhs in equity share capital, representing 82% of subsidiary's equity share capital
- The subsidiary was incorporated on 09 July 2026 to enter dermatology segment and baby care market
- The subsidiary commenced business operations in October 2026
- Pre-operative and incidental expenses of ₹335.60 Lakhs charged to Statement of Profit and Loss
- Exceptional items from previous year (FY26) consisted of incremental gratuity and leave liabilities amounting to ₹360.39 lakhs due to change in definition of "wages" under New Labour Code effective from 21 November 2025